G8 Agrees World Will Tackle Alzheimer’s, But Solutions Are Some Way Off
This article was originally published in The Pink Sheet Daily
The G8 dementia summit saw politicians, health stakeholders and financiers agree to target Alzheimer’s disease together, but a silver bullet may be years away.
You may also be interested in...
A group of pharmaceutical companies, charities and the UK government are funding the first venture capital fund targeted against a specific condition, dementia.
Australia’s Prana Biotech Phase II Data On Huntington’s Candidate Holds Investor Interest With More To Come
Australia’s Prana Biotechnology has Phase II clinical trial data on a potential Huntington’s disease therapy to sustain a surge in the share price over the past year with more possibly on the way for an Alzheimer’s therapy.
With the potential for a multi-billion-dollar blockbuster on its hands, Eli Lilly could conduct a confirmatory trial or even seek near-term approval of sola after pooled data revealed a hint of disease modifying potential in mildly affected Alzheimer’s patients, though the company also may be grasping at straws.